On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. The trial did not exclude any variants of SARS-CoV-2, the virus responsible for COVID-19.